In the period from 1956 through 1962, analytical chemistry and clinical pharmacology converged to enable measurement of drug components in biological samples and to tie those levels to patient outcomes. Practical separation techniques, notably paper chromatography, made it possible to resolve related antibiotic derivatives and to monitor them in clinical specimens, foreshadowing dedicated drug-monitoring assays. Concurrently, quantification of serum levels of anticonvulsants, notably diphenylhydantoin, and its correlation with clinical status and electroencephalographic responses, anchored therapeutic drug monitoring as a routine clinical tool. The literature also emphasized understanding drug absorption processes to interpret systemic exposure and underpin dosing decisions, forming early pharmacokinetic thinking that informed monitoring strategies. Across these efforts, the field began integrating pharmacodynamic assessment with concentration data, setting methodological standards for monitoring programs and guiding the interpretation of therapeutic drug levels.